Tacrolimus - The drug for the turn of the millennium?

被引:142
作者
Ruzicka, T [1 ]
Assmann, T [1 ]
Homey, B [1 ]
机构
[1] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany
关键词
D O I
10.1001/archderm.135.5.574
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Tacrolimus has been shown to be a powerful suppressor of the immune system. It was introduced into clinical use to prevent allograft rejection and is now routinely used in kidney, liver, and heart transplantation. Recently, 2 double-blind multicenter studies demonstrated the therapeutic efficacy of topical and systemic tacrolimus in the inflammatory skin diseases atopic dermatitis and psoriasis. Data Source: MEDLINE was searched for relevant publications and combined with our own clinical, in vitro, and in vivo studies. Study Selection: All studies dealing with tacrolimus and dermatology were reviewed. Data Extraction: Publications with clinically relevant data were included in this review. Conclusions: Topical tacrolimus is a safe and effective therapeutic agent that may open a new era in the treatment of inflammatory skin diseases, particularly for patients with atopic dermatitis. Before its full potential in dermatology can be assessed, more clinical experience in treating children and comparison with the criterion standard of anti-inflammatory therapy, glucocorticosteroids, are needed.
引用
收藏
页码:574 / 580
页数:7
相关论文
共 76 条
[1]  
ABUELMAGD K, 1991, TRANSPLANT P, V23, P3328
[2]   RESOLUTION OF SEVERE PYODERMA-GANGRENOSUM IN A PATIENT WITH STREAKING LEUKOCYTE FACTOR DISEASE AFTER TREATMENT WITH TACROLIMUS (FK-506) [J].
ABUELMAGD, K ;
VANTHIEL, DH ;
JEGASOTHY, BV ;
JACOBS, JC ;
CARROLL, P ;
RODRIGUEZRILO, H ;
ACKERMAN, CD ;
FUNG, JJ ;
STARZL, TE .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (07) :595-598
[3]   Comparison of acute rapamycin nephrotoxicity with cyclosporine and FK506 [J].
Andoh, TF ;
Burdmann, EA ;
Fransechini, N ;
Houghton, DC ;
Bennett, WM .
KIDNEY INTERNATIONAL, 1996, 50 (04) :1110-1117
[4]  
[Anonymous], 1996, Arch Dermatol, V132, P419
[5]   SUCCESSFUL TREATMENT OF RESISTANT FACIAL LESIONS OF ATOPIC-DERMATITIS WITH 0-CENTER-DOT-1-PERCENT FK506 OINTMENT [J].
AOYAMA, H ;
TABATA, N ;
TANAKA, M ;
UESUGI, Y ;
TAGAMI, H .
BRITISH JOURNAL OF DERMATOLOGY, 1995, 133 (03) :494-496
[6]  
BACHARACHBUHLES M, 1994, ACTA DERM-VENEREOL, V74, P79
[7]  
Behcet H., 1940, Dermatologica, V81, P73
[8]   INDUCTION OF FC-EPSILON-R2/CD23 ON HUMAN EPIDERMAL LANGERHANS CELLS BY HUMAN RECOMBINANT INTERLEUKIN-4 AND GAMMA-INTERFERON [J].
BIEBER, T ;
RIEGER, A ;
NEUCHRIST, C ;
PRINZ, JC ;
RIEBER, EP ;
BOLTZNITULESCU, G ;
SCHEINER, O ;
KRAFT, D ;
RING, J ;
STINGL, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (01) :309-314
[9]   PATHOGENESIS OF ATOPIC ECZEMA [J].
BOS, JD ;
KAPSENBERG, ML ;
SMITT, JHS .
LANCET, 1994, 343 (8909) :1338-1341
[10]   THE PRESENCE OF IGE MOLECULES ON EPIDERMAL LANGERHANS CELLS IN PATIENTS WITH ATOPIC-DERMATITIS [J].
BRUYNZEELKOOMEN, C ;
VANWICHEN, DF ;
TOONSTRA, J ;
BERRENS, L ;
BRUYNZEEL, PLB .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1986, 278 (03) :199-205